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Needle biopsies are taken as standard diagnostic specimens for many cancers, but no technique exists for the high-throughput
analysis of multiple individual immunohistochemical (IHC) markers using these samples. Here we present a simple and highly reliable
technique for constructing tissue microarrays (TMAs) from prostatic needle biopsies. Serial sectioning of the TMAs, called
‘Checkerboard TMAs’, facilitated expression analysis of multiple proteins using IHC markers. In total, 100% of the analysed biopsies
within the TMA both preserved their antigenicity and maintained their morphology. Checkerboard TMAs will allow the use of needle
biopsies (i) alongside other tissue specimens (trans-urethral resection of prostates and prostatectomies in the case of prostate
cancer) in clinical correlation studies when searching for new prognostic markers, and (ii) in a diagnostic context for assessing
expression of multiple proteins in cancers from patients prior to treatment.
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Needle biopsy specimens are taken at the time of diagnosis from
many human malignancies, including oral cancer, breast cancer,
sarcomas, prostate cancer and lymph node masses (Bostwick,
1997; Morrow et al, 2002; Neville and Day, 2002; Cormier and
Pollock, 2004; Jereczek-Fossa et al, 2004). In prostate cancer, for
example, examination of needle biopsy specimens yields valuable
information, including Gleason grade and the tumour extent, that
facilitates decision-making on the appropriate treatment. A major
current problem in prostate cancer is to predict the behaviour of
early and potentially localised disease (Yao and Lu-Yao, 2002).
Some cases may remain dormant for many years without
progressing, while others will progress rapidly to metastases. It
is therefore important to identify the patients who need to be
treated and separate them from those who can be managed by
active surveillance, thus sparing the latter of the adverse
consequences of unnecessary treatment (Dearnaley and Melia,
1997; Parker, 2004). If tests are to be developed that will allow the
prediction of clinical behaviour of patients diagnosed with prostate
cancer, for example, following prostate-specific antigen (PSA)
screening, it must be possible to perform the test on biological
specimens obtained from the patients at the time of diagnosis,
which would usually only include trans-rectal ultrasound (TRUS)-
guided needle biopsy specimens, blood or urine.
Tissue microarrays (TMAs) that allow many hundreds of
tumours to be analysed simply in a single experiment have proven
to be very useful in high-throughput evaluation of prognostic
markers for predicting the clinical behaviour of patients with
prostate cancer (Dhanasekaran et al, 2001; Rhodes et al, 2003;
Foster et al, 2004). At the moment, construction of TMAs in
prostate cancer studies is however limited to tissue samples
obtained from punched-out cores from paraffin blocks from trans-
urethral resection of prostate (TURP) specimens and from radical
prostatectomies. Battifora and Mehta (1990) described a Checker-
board method for producing tissue arrays as a forerunner to the
core-based TMA method described by Kononen et al (1998). In
this Checkerboard method, multiple (up to 100) chunks of
formalin-fixed de-paraffinised or fresh normal or tumour tissue
were reset in agar and then in paraffin wax in a Checkerboard
pattern. This procedure is unsuitable for formalin-fixed needle
biopsy specimens because, following dewaxing, the tiny specimens
are easily lost and very difficult to orientate and re-embed
vertically. The TMA procedure described by Kononen et al (1998)
is also unsuitable for use with prostate needle biopsy specimens.
The diameter of these needle biopsies, which are conventionally
embedded horizontally in paraffin blocks, is less than 1.26mm, the
outer diameter of an 18-G needle, and their depth is further eroded
after the block has been sectioned for diagnosis. Hence, cores
obtained by the Kononen et al (1998) method would be extremely
difficult to align in the recipient block, and at best would provide
only a few slices. We present an approach for constructing TMAs
from needle biopsy specimens that overcomes these difficulties.
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Selection of paraffin blocks containing prostate needle
biopsies
Paraffin-embedded formalin-fixed prostate needle biopsy speci-
mens (Figure 1A) were obtained from prostate cancer patients (i)
who took part in the RT01 trial at The Royal Marsden Hospital
NHS Trust and had given written consent for research to be
undertaken on their biopsies (including their 2-year post radio-
therapy biopsies) (n¼2); (ii) who had diagnostic TRUS-guided
prostate biopsies at the St Georges Hospital NHS Trust (n¼23).
The biopsies from the former group of patients were only used in
the pilot experiments (data not shown). Biopsies from the latter
group of patients were used in the validation set of TMAs and all
patients in this group had died at the time of the study.
Antibodies
The following antibodies were chosen: (i) low-molecular-weight
keratin, CAM 5.2 (cat# 345779, supplied by Becton Dickinson,
dilution 1:5), chosen to show all epithelial cells; (ii) high-
molecular-weight keratin, LP34 (cat# M0717, supplied by Dako-
Cytomation, dilution 1:50) that stains only basal cells and (iii)
PSA (rabbit polyclonal, cat# A0562, supplied by DakoCytomation,
dilution 1:20000) that stains prostatic epithelial cells of acini and
peripheral ducts.
Immunohistochemistry (IHC)
Sections of the Checkerboard TMA were cut at 3mm onto
Superfrost Plust positively charged glass slides (Menzel-Glaser,
Germany), dewaxed with xylene and rehydrated to water through
graded ethanol rinses. Endogenous peroxidase activity was blocked
by immersion of tissue sections in a 10% (vv
 1) solution of H2O2
in deionised water at room temperature for 8min. In all, 1l of
diluted (1:10 in deionised water) Tris-EDTA-citrate (pH 7.8)
buffer was preheated in a pressure cooker (Nordicware microwave
tender cooker, Bio Genex) for 16min without the slides. High-
temperature antigen retrieval was then performed by placing the
peroxidase-blocked slides in the hot buffer and sealing the
pressure cooker, and comprised microwave (Panasonic 900W)
heating at high temperature for 6min. After this, the pressure was
released and cold water was allowed to run in the pressure cooker
to cool the slides, which were now ready for staining. Chymo-
trypsin pretreatment was performed by placing the peroxidase-
blocked slides in a chymotrypsin (Alpha Chymotrypsin Type II
bovine pancreas, Sigma Cat# C-4129) solution in Tris buffer (pH
7.6) for 30min. The slides were then washed by running tap water
on them for 5min. Staining after the primary antibody incubation
involved the use of ChemMate Envision Kit K5007 from
Dakocytomation, and the Optimax Plus Staining Machine (Bio-
Genex, supplied by A Menarini) and manufacturer’s instructions
were followed. Sections were incubated with the primary antibody
for 30min at room temperature and washed with buffer (Optimax
Wash buffer – BioGenex supplied by A Menarini Cat. No. HK583-
5K).
RESULTS
Preparation of individual blocks or ‘checkers’
The starting point for construction of Checkerboard TMAs was
paraffin donor blocks containing formalin-fixed prostate needle
biopsy specimens embedded at their surface (Figure 1A). A scalpel
blade was used to cut 4mm lengths of biopsy specimens
corresponding to areas of tumour or normal tissue identified
from the original haematoxylin and eosin (H&E)-stained long-
itudinal section by the study histopathologist (CMC). Additional
cuts were made in the wax to obtain a 4 2 2mm
3 cubical
shaped block, which we called a ‘biopsy checker’, containing the
4mm length of biopsy specimen attached on one of its 4 2mm
2
faces. To help orientate the block in later stages of the procedure,
the 4 2mm
2 face opposite that containing the biopsy specimen
was immediately painted with dyes – blue and red dyes were used
to paint this face on alternate checkers (Figure 1B).
Construction of the Checkerboard TMA
The checkers were then arranged in a square grid pattern in a
36 24 5mm
3 stainless steel mould (Raymond A Lamb Ltd, UK)
(Figure 1C). The checkers were positioned in the mould so that
each biopsy specimen had a vertical orientation allowing analysis
of the cross-section of each biopsy. The mould was placed on the
semiheated platform of the embedding apparatus, while the
checkers were arranged. A predetermined template was used as a
guide to position and record the identity of each checker within the
array. A plastic cassette was then placed over the mould. The
checkers were then re-embedded by pouring hot paraffin wax
(601C) into the mould through the cassette and the mould was then
cooled by placing it on a cold platform ( 51C) for 1h. Gentle
Figure 1 Construction of Checkerboard TMA from prostatic needle biopsies. (A) Prostatic needle biopsies embedded horizontally within a paraffin block
(bottom) and H&E sections from this block (top). (B) Checkers (4 2 2mm
3) cut from the original paraffin block containing the prostatic needle biopsy
specimen was painted on the surface opposite that containing the biopsy, alternately with blue and red dyes. (C) Checkers positioned in a 36 24 5mm
3
stainless steel mould (Raymond A Lamb Ltd, UK) so that each biopsy specimen now had a vertical orientation. (D) Finished Checkerboard TMA block in
which the cross-sections of the vertically positioned biopsies are seen (arrow). (E) Haematoxylin and eosin-stained section (4mm) obtained from the
Checkerboard TMA block.
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srocking of the mould in a circular fashion was carried out while the
hot paraffin wax was being poured to ensure that each checker was
completely surrounded by wax. Sufficient care was taken to avoid
formation of air bubbles in the wax between the checkers. The
dyed surfaces of the checkers are monitored: (i) to mark the
position of the checkers within the finished paraffin block attached
to the plastic cassette and (ii) to ensure that the checkers remain in
their correct orientation during the setting process. The alternate
marking of individual checkers with blue and red dyes gave rise to
a Checkerboard appearance (Figure 1D). Initial sections (4mm) cut
onto Superfrostt glass slides (Ultima) were stained by conven-
tional H&E stains to identify the location and morphology of
representative biopsy specimens within the microarray block
(Figure 1E).
Analysis of IHC markers using Checkerboard TMAs
Tissue microarrays were constructed from biopsies from deceased
prostate cancer patients (n¼23). In all, 45 checkers were prepared
from needle biopsies from these 23 patients. Out of the 45
checkers, 41 retained their biopsy specimens in the Checkerboard
TMA, equivalent to a tissue loss of 9%. The remaining checkers
included 22 biopsy specimens that had regions considered to
contain cancer based on the original H&E section of the
horizontally embedded biopsy, and 19 that had been judged as
normal.
Results of IHC studies on 123 individual tissue slices from the
Checkerboard TMA demonstrated that antigenicity was preserved
in 100% of the retained biopsies. Results from serial sections
Figure 2 Analysis of sections obtained from a Checkerboard TMA. (A) Serial sections ( 20) from a single biopsy specimen that contained both cancer
(thin arrow) and prostatic intra-epithelial neoplasia (PIN) (arrowhead) stained by H&E, PSA, CAM 5.2 and LP34. (B) Serial sections ( 20) of second biopsy
specimen containing both cancer (thin arrow) in the deeper part of the biopsy and benign glands on the surface (arrowhead) stained by H&E, PSA, CAM 5.2
and LP3. The surface of the biopsy that was originally cut for diagnosis of cancer is seen (dotted arrow). (C) Comparison of a tissue core ( 20) from
conventional TMA (top panel) with a biopsy core ( 20) from the Checkerboard TMA (lower panel). The side of the needle biopsy originally cut for
diagnostic purposes can be seen (arrow).
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s(3–4mm) of two representative biopsy specimens within the
Checkerboard TMA containing cancer stained by H&E, PSA, CAM
5.2 (low-molecular-weight keratin) and LP34 (high-molecular-
weight keratin) are shown (Figures 2A and B). The PSA, CAM 5.2
and LP34 antibodies are used routinely in the diagnosis of prostate
cancer (Moll et al, 1982; Makin et al, 1984; Gillespie et al, 2002;
Evans, 2003). An interesting feature of the Checkerboard TMA
analyses was that cancer was identified in nine out of 19 (five out
of 19 based on H&E staining alone) checkers containing biopsy
specimens originally judged as normal.
A comparison of a section of core obtained from conventional
TMA with that obtained from Checkerboard TMA method
described in this report is shown in Figure 2C. The cross-sections
are very similar in size, but the tissue specimen from the
Checkerboard TMAs generally has a more irregular shape and
the side of the needle biopsy originally cut for diagnostic purposes
can usually be seen (Figure 2C, arrow).
DISCUSSION
We have demonstrated that it is possible to construct TMA from
diagnostic prostate needle biopsies. Prostate needle biopsies are
formalin fixed and set horizontally on the surface of a paraffin wax
block so that a lengthwise slice of the entire biopsy specimen can
be taken for diagnostic examination. Our method for constructing
TMAs from these specimens involves cutting out small 4mm
lengths of the biopsy specimen and repositioning them in a vertical
orientation so that approximately 90–100 4-mm-thick sections
from each biopsy can be made available for IHC staining, in
comparison to only a few from the original horizontally embedded
specimens. Such formalin-fixed material could also, in principle,
be used for other molecular procedures such as fluorescence in situ
hybridisation (FISH) (Takahashi et al, 1994; Bastacky et al, 2004).
The IHC staining results from our study show that the biopsy
tissue maintains its antigenicity even after embedding at the
surface of the paraffin block and re-embedding the biopsy
checkers in the Checkerboard TMAs. Using conventional TMA
technology, Rubin et al (2002) concluded that less than three cores
may not accurately represent protein expression, but that more
than four cores were unnecessary and did not add to the value of
arrays used to predict prostate cancer outcome. In the method
described here, multiple assessments of protein expression could
be made by analysing tumour from different biopsy cores or from
tumour at different depths within an individual core. Notably, the
H&E and IHC analyses of cross-sections of cores in the Checker-
board TMAs detected cancer in nearly one-half of biopsies
originally judged as normal by conventional H&E analyses of the
biopsies. Such a finding may in part be due to the improved
sensitivity allowed by use of H&E and IHC in combination, and in
part achieved by the inherent advantage of this technique in being
able to examine a greater depth of tissue. In the current series, this
finding did not result in any new cancer diagnosis because all
samples were taken from patients who had already been diagnosed
with prostate cancer. However, in future studies, it may well be
interesting to compare the results obtained in conventional
diagnosis using needle biopsy specimens with those obtained
from H&E and IHC analyses on cross-sections from Checkerboard
TMAs.
Other investigators have reported a 10–30% loss of tissue when
constructing conventional TMAs from a large number of cores
using manual or automated methods (Schraml et al, 1999; Mucci
et al, 2000; Hoos and Cordon-Cardo, 2001; Mengel et al, 2003).
This compares to a 9% tissue loss reported in this study. Our low
level of loss may indicate that re-embedding the checkers using hot
paraffin wax holds the cores more tightly compared to conven-
tional TMA, where the recipient wax block is softened at 361Ct o
secure the cores.
Needle biopsies provide vital information about the biology and
natural history of the cancer (Sotiriou et al, 2002) and microarray
studies are showing great promise in providing diagnostic as well
as prognostic information in a variety of cancers (Pusztai et al,
2003). Tissue microarray studies in prostate cancer evaluating
predictive markers have, however, been limited to TURP and
radical prostatectomy specimens (Bubendorf et al, 1999; Dhana-
sekaran et al, 2001; Foster et al, 2004). Trans-rectal ultrasound-
guided biopsies now predominantly provide diagnostic tissue, but
are in general unsuitable for construction of TMA using
conventional methods, because of the orientation of the small
biopsies. The technique for the production of TMAs from needle
biopsy specimens allows formalin-fixed prostatic needle biopsy
specimens to be used: (i) in a diagnostic context for assessing
multiple IHC markers in patients prior to treatment and (ii)
together with both TURP and radical prostatectomy specimens in
high-throughput screening for new prognostic markers. The
analysis of multiple markers in prostate cancer is important
because it may be the analysis of a combination of markers rather
than a single marker that provides the best prognostic information
(Tricoli et al, 2004). This technique may additionally be applicable
in analysing needle biopsies taken from other cancer types.
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